Market Overview:
The global group B streptococcus (GBS) infection treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of GBS infections, rising demand for novel antibiotics, and growing awareness about GBS infections. The prenatal-onset Gbs disease segment is expected to account for the largest share of the global group B streptococcus (GBS) infection treatment market in 2018. This segment is expected to grow at a CAGR of 5.8% from 2018 to 2030.
 Infection Treatment Industry Outlook.svg)
Product Definition:
Group B Streptococcus (GBS) is a type of bacteria that can cause a number of infections, including respiratory infections, meningitis, and sepsis. GBS infection treatment usually involves antibiotics. The importance of GBS infection treatment lies in the fact that it can often be deadly if not treated properly.
Prenatal-onset Gbs Disease:
Prenatal-onset GBS disease is a rare disorder that affects the central nervous system of the fetus. It is an early-onset form of group B streptococcus (GBS) infection, which usually occurs in women between 20 and 30 weeks gestation. The presence of antibodies against GBS in a pregnant woman can cause preterm delivery or stillbirths, depending on the severity of illness at childbirth.
Early-onset Gbs Disease:
Early-onset GBS disease is a rare form of the infection caused by Group B Streptococcus. It usually affects infants and children, although it can occur in adults as well. The condition has no symptoms; therefore, diagnosis is made based on tests conducted for the presence of antibodies against GBS toxins in the patient’s blood or urine sample.
Application Insights:
Based on the application, the Group B streptococcus infection treatment market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacy segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as a large patient base with chronic diseases associated with GBS infections and rising awareness about early diagnosis of GBS infections among pregnant women.
The retail pharmacy segment is expected to grow at a lucrative rate over the forecast period owing to increasing incidence rates of late-onset GBS disease among adults which has resulted in high demand for antifungal and antibiotic drugs from general practitioners (GPs). In addition, due to easy availability of drugs at low costs through this channel compared to hospitalization or medical consultation fees are expected to be reduced which will further fuel growth during the forecast period.
Regional Analysis:
Europe dominated the global market in terms of revenue share in 2017. The presence of well-established healthcare facilities, favorable reimbursement policies, and rising awareness levels among pregnant women are some factors driving the regional market growth. In addition, increasing incidence rates of GBS infections are also expected to spur regional demand for treatment over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rapidly improving healthcare infrastructure and growing medical tourism industry in emerging economies such as India and China.
Growth Factors:
- Rising incidence of GBS infection: The incidence of GBS infection is rising globally due to various factors such as increasing population, changing lifestyle, and growing awareness about the disease. This is expected to drive the demand for GBS infection treatment products in the coming years.
- Growing number of product approvals: The number of product approvals for the treatment of GBS infections is growing rapidly, owing to the increasing research and development activities in this area. This is likely to boost the growth of the market in future.
- Increasing demand for novel therapies: There is a growing demand for novel therapies for treating GBS infections, as these offer better efficacy and safety profiles than traditional treatments options. This will spur market growth in future years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Group B Streptococcus (GBS) Infection Treatment Market Research Report
By Type
Prenatal-onset Gbs Disease, Early-onset Gbs Disease, Late-onset Gbs Disease
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Pfizer Inc., Alopexx Enterprises, LLC, Wellstat Vaccines LLC, Minervax ApS, Novartis, GlaxoSmithKline
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Group B Streptococcus (GBS) Infection Treatment Market Report Segments:
The global Group B Streptococcus (GBS) Infection Treatment market is segmented on the basis of:
Types
Prenatal-onset Gbs Disease, Early-onset Gbs Disease, Late-onset Gbs Disease
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer Inc.
- Alopexx Enterprises, LLC
- Wellstat Vaccines LLC
- Minervax ApS
- Novartis
- GlaxoSmithKline
 Infection Treatment Market Overview.svg)
Highlights of The Group B Streptococcus (GBS) Infection Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prenatal-onset Gbs Disease
- Early-onset Gbs Disease
- Late-onset Gbs Disease
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Group B Streptococcus (GBS) Infection Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Infection Treatment Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Group B Streptococcus (GBS) infection is treated with antibiotics.
Some of the major companies in the group b streptococcus (gbs) infection treatment market are Pfizer Inc., Alopexx Enterprises, LLC, Wellstat Vaccines LLC, Minervax ApS, Novartis, GlaxoSmithKline.
The group b streptococcus (gbs) infection treatment market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Group B Streptococcus (GBS) Infection Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Group B Streptococcus (GBS) Infection Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Group B Streptococcus (GBS) Infection Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Group B Streptococcus (GBS) Infection Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Group B Streptococcus (GBS) Infection Treatment Market Size & Forecast, 2018-2028
4.5.1 Group B Streptococcus (GBS) Infection Treatment Market Size and Y-o-Y Growth
4.5.2 Group B Streptococcus (GBS) Infection Treatment Market Absolute $ Opportunity
Chapter 5 Global Group B Streptococcus (GBS) Infection Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Type
5.2.1 Prenatal-onset Gbs Disease
5.2.2 Early-onset Gbs Disease
5.2.3 Late-onset Gbs Disease
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Group B Streptococcus (GBS) Infection Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Group B Streptococcus (GBS) Infection Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Group B Streptococcus (GBS) Infection Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Type
9.6.1 Prenatal-onset Gbs Disease
9.6.2 Early-onset Gbs Disease
9.6.3 Late-onset Gbs Disease
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Group B Streptococcus (GBS) Infection Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Type
10.6.1 Prenatal-onset Gbs Disease
10.6.2 Early-onset Gbs Disease
10.6.3 Late-onset Gbs Disease
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Group B Streptococcus (GBS) Infection Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Type
11.6.1 Prenatal-onset Gbs Disease
11.6.2 Early-onset Gbs Disease
11.6.3 Late-onset Gbs Disease
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Group B Streptococcus (GBS) Infection Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Type
12.6.1 Prenatal-onset Gbs Disease
12.6.2 Early-onset Gbs Disease
12.6.3 Late-onset Gbs Disease
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Group B Streptococcus (GBS) Infection Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Type
13.6.1 Prenatal-onset Gbs Disease
13.6.2 Early-onset Gbs Disease
13.6.3 Late-onset Gbs Disease
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Group B Streptococcus (GBS) Infection Treatment Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Group B Streptococcus (GBS) Infection Treatment Market: Competitive Dashboard
14.2 Global Group B Streptococcus (GBS) Infection Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer Inc.
14.3.2 Alopexx Enterprises, LLC
14.3.3 Wellstat Vaccines LLC
14.3.4 Minervax ApS
14.3.5 Novartis
14.3.6 GlaxoSmithKline
